Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation) (English, HTML)
View metadata and access the original English HTML file: Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation).
- Format
- HTML
- Access
- file-only
- Publisher-reported update
- 2024-05-09
Health Canada carried out a safety review to investigate the potential risk of developing an abnormal heart rhythm (QT interval prolongation) with the use of over-the-counter (OTC) drug products containing loratadine. This safety review was triggered by a publication, in the World Health Organization (WHO) Pharmaceuticals NewsletterFootnote1, describing cases of an abnormal heart rhythm (QT interval prolongation) possibly associated with the use of loratadine and desloratadine.
Data overview
- Formats
- HTML
- File languages
- English
- Available actions
- Access original file